South San Francisco biotech Exelixis and partner Roche say their in-development combo treatment for melanoma extended survival in an early-stage trial, setting the stage for Phase III results that could make or break the treatment’s future.

…read more

Source: Roche and Exelixis tout PhI cancer combo with late-stage data on the way